Navigation Links
Ranbaxy In-Licences NDDS Analgesic Molecule From Ethypharm

Ranbaxy Laboratories Limited today entered into an in-licensing agreement with Ethypharm S.A., France for novel drug delivery system (NDDS) analgesic // , Tramadol in the Indian market The agreement was signed with Ethypharm LL India (Ethypharm), the wholly-owned subsidiary of the French drug major for 50 mg strength, the company said in a statement.

The product will be supplied from Ethypharm's manufacturing facility near Mumbai and marketed and distributed by Ranbaxy under its brand name 'Trambax', it added.

Commenting on the agreement Ranbaxy India and Middle East Regional Director Sanjeev I Dani, said, the introduction of Trambax tablets will further strengthen thecompany's portfolio in the pain management segment.

'The Indian market of Tramadol is approximately Rs 15 crores annually and is expected to grow significantly with the addition of this Novel Drug Delivery System, making the administration of the product easier and more convenient to the patient,' Ethypharm LL India Chief Executive Officer Ajey Kumar said.

Curently, Ranbaxy has a basket of 30 novel products already on pharmacy shelves in the NDDS space in India. With the introduction of the NDDS product Trambax, Ranbaxy has so far launched 2 in-licenced products and has 5 more such products in the pipeline, for launch during the year, it added.

Tramadol is used for treatment of severe to moderate pain in trauma cases and is also used as an adjunct therapy in the treatment of cancer patients.

Source:PTI News
'"/>




Page: 1

Related medicine news :

1. Ranbaxy joins hand with Cipla to co-market ciprofloxacin
2. Ranbaxy gets US FDA approval for Lisinopril
3. Ranbaxy Labs Entry Into Anti-Acne Market
4. Ranbaxy trying to make inroads in herbal drugs market
5. Lamivudine Manufactured By Ranbaxy gets the nod from the US FDA
6. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
7. Ranbaxy opens Drug discovery centre in Gurgaon
8. Ranbaxy Laboratories All Set To Export Bird Flu Vaccines
9. SRL Ranbaxy offers quicker bird flu diagnostic test
10. Diagnostic Test Launched by Ranbaxy for En Masse Screening of Bird Flu
11. Ranbaxy Launches Once-a-day Inhaler For Asthma Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/23/2017)... ... June 23, 2017 , ... "The Better Care Reconciliation Act ... harm to people with all chronic conditions, including mental illnesses, while increasing the ... the Affordable Care Act (ACA) requirement that insurers cover pre-existing conditions, it does ...
(Date:6/23/2017)... ... ... Studies show evidence that carotenoids and antioxidants derived either from the diet or from ... how often do ophthalmologists and optometrists in Sweden recommend the use of nutritional supplements, ... symptoms of AMD? A study published recently in Dove Medical Press journal, ...
(Date:6/23/2017)... ... June 23, 2017 , ... Military Connection friend and veteran ... the JFK Virgin Atlantic lounge. , Bensko is no stranger to the plight ... Bensko dedicated her life to supporting our wounded veterans. A world-class photographer, her riveting ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Aesthetic Channel has recently highlighted ... has come up with a proprietary technique that he calls the AuraLyft ... dropped. For all ages, patients can expect to look refreshed, rejuvenated, and revitalized. ...
(Date:6/23/2017)... ... ... 21 Middle East and South Asia Leaders Selected as Eisenhower Fellows , ... society in 11 countries across the Middle East and South Asia to embark on ... knowledge and ideas with the leading minds in their fields. , For the ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... June 7, 2017 Endo International plc (NASDAQ: ... 2017, the Hon. Joseph R. Goodwin , U.S. ... West Virginia , entered a case management ... Repair System Products Liability Litigation (the "MDL") that includes ... to provide expert disclosures on specific causation within one ...
(Date:6/3/2017)... 3, 2017  Eli Lilly and Company (NYSE: ... from the Phase 3 MONARCH 2 study showed ... inhibitor, in combination with fulvestrant, significantly improved progression-free ... in women with hormone-receptor-positive (HR+), human epidermal growth ... have relapsed or progressed after endocrine therapy (median ...
(Date:5/30/2017)... May 30, 2017 Therapix Biosciences Ltd. (Nasdaq: ... in the development of cannabinoid-based drugs, today announced ... overview at three upcoming scientific and investor conferences ... Micro Invitational: ... Date:                     Wednesday, ...
Breaking Medicine Technology: